Related references
Note: Only part of the references are listed.Regulation Mechanisms and Signaling Pathways of Autophagy
Congcong He et al.
ANNUAL REVIEW OF GENETICS (2009)
MYC Activity Mitigates Response to Rapamycin in Prostate Cancer through Eukaryotic Initiation Factor 4E-Binding Protein 1-Mediated Inhibition of Autophagy
Bala S. Balakumaran et al.
CANCER RESEARCH (2009)
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2009)
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer
Elizabeth Iorns et al.
CANCER CELL (2008)
A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer
Maiea Chanrion et al.
CLINICAL CANCER RESEARCH (2008)
A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance
Julia S. Samaddar et al.
MOLECULAR CANCER THERAPEUTICS (2008)
A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival
Arul M. Chinnaiyan et al.
NEOPLASIA (2008)
A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer
Neil Johnson et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Overload of the heat-shock protein H11/HspB8 triggers melanoma cell apoptosis through activation of transforming growth factor-β-activated kinase 1
B. Li et al.
ONCOGENE (2007)
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Potential therapeutic applications of autophagy
David C. Rubinsztein et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant
Meiyun Fan et al.
CANCER RESEARCH (2006)
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome
Jonna Frasor et al.
CANCER RESEARCH (2006)
Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells
Danielle Meijer et al.
MOLECULAR CANCER RESEARCH (2006)
Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors
CJ Creighton et al.
CANCER RESEARCH (2006)
Autophagy and signaling: their role in cell survival and cell death
P Codogno et al.
CELL DEATH AND DIFFERENTIATION (2005)
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival
LD Miller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The significance of autophagy in cancer
G Ng et al.
MOLECULAR CARCINOGENESIS (2005)
Overview of tyrosine kinase inhibitors in clinical breast cancer
A Agrawal et al.
ENDOCRINE-RELATED CANCER (2005)
Building a human kinase gene repository: Bioinformatics, molecular cloning, and functional validation
J Park et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling
MPHM Jansen et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The role of autophagy in cancer development and response to therapy
Y Kondo et al.
NATURE REVIEWS CANCER (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Regulation and role of autophagy in mammalian cells
AJ Meijer et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2004)
Diagnosis of multiple cancer types by shrunken centroids of gene expression
R Tibshirani et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
K Yu et al.
ENDOCRINE-RELATED CANCER (2001)